Related by context. All words. (Click for frequent words.) 58 volociximab 56 TG# [001] 56 drug conjugate 56 TRX# 56 RP# [002] 56 epothilone 56 CG# [001] 56 oral prodrug 55 XL# XL# 55 IMC #B 55 DEB# 55 PSMA ADC 55 XL# [003] 55 liposomal formulation 55 investigational humanized monoclonal antibody 55 AKT inhibitor 55 LymphoStat B TM 54 MEK inhibitor 54 RhuDex ® 54 Panzem R NCD 54 mertansine 54 systemically administered 54 FOLOTYN ® 54 vidofludimus 54 cetuximab Erbitux ® 53 ARIKACE ™ 53 generation purine nucleoside 53 RH1 53 Archexin 53 Tasimelteon 53 Blinatumomab 53 Belinostat 53 humanized monoclonal antibody 53 Quinamed 53 humanized anti 53 CD3 monoclonal antibody 53 Phase IIa trials 53 Aplidin R 53 E1 INT TM 53 Elagolix 53 Antiviral Activity 53 PRX# 53 paclitaxel Taxol ® 53 R#/MEM 53 Onconase 53 gefitinib Iressa 53 non nucleoside inhibitor 53 humanized antibody 52 Apoptone 52 EP# [003] 52 oral proteasome inhibitor 52 gallium containing 52 proteasome inhibitor 52 HCD# [002] 52 elotuzumab 52 Factor VIIa 52 EndoTAG TM -1 52 opioid induced bowel dysfunction 52 TH# [003] 52 ARC# [001] 52 PKC# 52 PI3K/Akt pathway inhibitor 52 HuLuc# 52 pan HDAC inhibitor 52 CYC# 52 EGFR HER2 52 adecatumumab MT# 52 anticancer compound 52 Phase Ib study 52 Pralatrexate 52 Proxinium TM 52 Vicriviroc 52 HDAC Inhibitor 52 XL# XL# XL# 52 HCV protease inhibitor 52 Antibody Drug Conjugate 52 trastuzumab DM1 T DM1 52 Uvidem 52 Phase Ib II 52 Pazopanib 51 receptor tyrosine kinase inhibitor 51 UVIDEM 51 DB# [003] 51 Cethrin R 51 IMA# 51 ATL# [001] 51 Phase 2b clinical trials 51 PEG SN# 51 MET inhibitor 51 anti EGFR antibody 51 IMC A# 51 Ceflatonin 51 Epratuzumab 51 Xeloda ® 51 ZACTIMA 51 candidate CRLX# 51 PI3K inhibitor 51 cilengitide 51 metastatic hormone refractory 51 HGS ETR2 51 huC# DM4 51 MET RET 51 docetaxel Taxotere R 51 GV# [001] 51 dasatinib Sprycel ® 51 metaglidasen 51 IAP inhibitors 51 bardoxolone 51 Traficet EN 51 Aplidin 51 TRC# 51 protein kinase inhibitor 51 MAXY alpha 51 erlotinib Tarceva ® 51 JAK2 inhibitor 51 UPLYSO 51 Plicera 51 MEK inhibitors 51 targeting CD# 51 selective kinase inhibitor 51 Panzem 51 CD# CEA 51 PLX# 51 investigational monoclonal antibody 51 docetaxel Taxotere ® 51 PDE4 inhibitor 51 ATL# [002] 51 AT# [002] 51 AEG# 51 Tesetaxel 51 BAL# [002] 51 HuMax CD# 51 JAK inhibitor 51 polymerase inhibitor 51 TMC# [002] 51 DMTS 51 MNTX 51 fosbretabulin 50 ulimorelin 50 GW# [003] 50 cancer neuroendocrine tumor 50 novel histone deacetylase 50 veltuzumab 50 refractory chronic lymphocytic 50 deforolimus 50 TELINTRA 50 DXL# 50 IAP inhibitor 50 SAR# [004] 50 relapsed refractory multiple myeloma 50 PNP inhibitor 50 Immunotherapeutic 50 Ofatumumab 50 LEP ETU 50 pertuzumab 50 Trastuzumab 50 panitumumab Vectibix 50 TRX1 50 Bicifadine 50 Phase Ib clinical 50 Tarvacin 50 Guanilib 50 Pemetrexed 50 ocrelizumab 50 HGS ETR1 50 Clolar ® 50 Phase IIIb clinical 50 PrevOnco ™ 50 oral gallium 50 Hormone Refractory Prostate Cancer 50 Virulizin ® 50 CYT# potent vascular disrupting 50 CD# monoclonal antibody 50 ularitide 50 VEGF Trap 50 Cloretazine ® 50 JAK3 50 Phase 1b 50 Aflibercept 50 forodesine 50 CBLC# 50 angiogenesis inhibitor 50 histone deacetylase HDAC inhibitor 50 MAGE A3 ASCI 50 Hsp# Inhibitor 50 mAb 50 enzastaurin 50 immunomodulatory therapy 50 Velcade bortezomib 50 baminercept 50 Ceflatonin R 50 JAK inhibitors 50 orally bioavailable 50 Sym# 50 Aurexis 50 Ixempra 50 Phase #b/#a 50 DU #b 50 Troxatyl 50 histone deacetylase inhibitor 50 cannabinor 50 gemcitabine Gemzar ® 50 bortezomib Velcade 50 PLK1 SNALP 50 alagebrium 50 vascular disrupting agent 50 eniluracil 49 MBP# [001] 49 Daclizumab 49 DG# [001] 49 XL# anticancer compounds 49 Xanafide 49 PF # [002] 49 Elotuzumab 49 Allovectin 7 49 HuMax EGFr 49 L BLP# 49 GED aPC 49 dacetuzumab 49 CCX# 49 PROVENGE ® 49 BENLYSTA ® 49 alpha#beta# integrin 49 CCR9 antagonist 49 TASQ 49 AQ4N 49 imatinib Gleevec ® 49 Omacetaxine 49 vemurafenib 49 CD# antibody [001] 49 BiTE 49 AEGR 49 EGS# 49 ISTODAX 49 Albuferon TM 49 PrevOnco 49 SRT# [003] 49 ALN TTR 49 Aptivus ® 49 MT# MEDI 49 obatoclax 49 Azedra 49 CCR5 antagonist 49 anticancer agent 49 Fx #A 49 ridaforolimus 49 Tamibarotene 49 Differential Quadrature Phase 49 Symadex 49 CB# [002] 49 Erlotinib 49 KN# [001] 49 signal transduction inhibitor 49 Nexavar ® 49 Voreloxin 49 Tarceva erlotinib 49 FOLFOX6 49 AS# amonafide L malate 49 Anticalin R 49 alvespimycin 49 trodusquemine 49 Panzem R 49 relapsed multiple myeloma 49 TOCOSOL Paclitaxel 49 Gemzar ® 49 MDV# 49 Solazed 49 PF # [001] 49 preclinical efficacy 49 investigational immunotherapy 49 Gemcitabine 49 Annamycin 49 Cimzia TM 49 Leukotriene 49 MyVax R 49 Bezielle 49 Amigal 49 Canvaxin TM 49 XL# XL# XL# XL# 48 PRT# 48 selective androgen receptor modulator 48 #D#C# 48 XmAb# 48 antiangiogenic therapy 48 JAK1 48 TKM ApoB 48 Initiate Phase 48 trastuzumab emtansine T DM1 48 seliciclib CYC# 48 registrational trial 48 PXD# 48 mTOR inhibitors 48 Aeroquin 48 INT# [002] 48 HQK 48 Ambrisentan 48 Neulasta ® 48 Phase IIb clinical trials 48 evaluating tivozanib 48 rNAPc2 48 Dacogen injection 48 Bortezomib 48 OvaRex R 48 Virulizin 48 ZK EPO 48 TBC# 48 Phase #/#a trial 48 NVA# 48 orally administered inhibitor 48 Telintra 48 subcutaneous dosing 48 Mipomersen 48 Phase IIa clinical trials 48 Actilon 48 MT# [002] 48 PD# [005] 48 BCX# 48 pharmacodynamic PD 48 initiate Phase 1b 48 amrubicin 48 ORENCIA ® 48 Dasatinib 48 Insegia 48 NXL# 48 bendamustine 48 RITUXAN 48 Panitumumab 48 OvaRex ® MAb 48 maximally tolerated dose 48 radiation sensitizer 48 SARMs 48 Adenuric 48 recurrent NSCLC 48 AZILECT R 48 Phase IIB 48 Phase 1a 48 subcutaneous formulation 48 CR# vcMMAE 48 pradefovir 48 Azedra TM 48 eprotirome 48 Pivotal Phase 48 metastatic renal cell carcinoma 48 BLA filing 48 Viramidine 48 OXi# 48 trabectedin 48 pediatric acute lymphoblastic 48 Bayer Onyx 48 CIMZIA TM 48 tanespimycin 48 Panzem NCD 48 Antisense 48 evaluating satraplatin 48 LymphoStat B belimumab 48 Amplimexon 48 GALNS 48 BRAF inhibitor 48 HIV integrase inhibitor 48 CD# antibodies 48 combinability 48 cetuximab Erbitux R 48 lumiliximab 48 depsipeptide 48 oral ridaforolimus 48 Anticalin 48 Sapacitabine 48 CEQ# 48 SU# [003] 48 virus HCV protease inhibitor 48 proteasome inhibitor bortezomib 48 demonstrated antitumor activity 48 multiple myeloma MM 48 ONX 48 Aurora kinase 47 R#/MEM # 47 PROSTVAC TM 47 otelixizumab 47 INCB# [001] 47 dacarbazine DTIC 47 PARP inhibitors 47 PD LID 47 BAY #-# 47 PEGPH# 47 NGX# 47 Androxal TM 47 Glufosfamide 47 Phase 2a Clinical Trial 47 FLT3 47 Nanobody 47 ORENCIA R 47 R roscovitine 47 ALN RSV# 47 Randomized Phase 47 CRLX# 47 isoform selective 47 castration resistant prostate cancer 47 dirucotide 47 ZD# [001] 47 BrachySil TM 47 galiximab 47 IIIb 47 phase IIb trial 47 Rifamycin SV MMX 47 DU# [002] 47 OMP #M# 47 Alfimeprase 47 TREANDA 47 Cloretazine R VNP#M 47 HGS# 47 YONDELIS 47 subcutaneously administered 47 BiTE antibody 47 methylnaltrexone 47 hypoxia activated prodrug 47 Tarvacin TM 47 ASONEP 47 Vitaxin 47 CoFactor 47 Targretin 47 tumor xenograft models 47 ganetespib 47 Tocosol Paclitaxel 47 Octreotide 47 MGd 47 BEMA TM Fentanyl 47 Revlimid lenalidomide 47 ZOLINZA 47 Specifid 47 huN# DM1 47 HCV protease 47 RG# [001] 47 RGDX 47 Phase #b/#a clinical 47 cetuximab Erbitux 47 Amrubicin 47 urocortin 2 47 Enzastaurin 47 IIIa 47 Phase Ib 47 tramiprosate Alzhemed TM 47 lesinurad 47 ASA# 47 cediranib 47 Dapagliflozin 47 RGB # 47 CCX# B 47 KNS # 47 ARRY # 47 sodium glucose cotransporter 47 Tyrima 47 ONTAK 47 mapatumumab 47 elacytarabine 47 BNC# 47 phase IIb clinical 47 alkylating agent 47 TASKi2 47 thymalfasin 47 T1c 47 lapatinib Tykerb 47 posaconazole 47 pralatrexate 47 multi kinase inhibitor 47 EOquin 47 Exelixis compounds 47 GRNVAC1 47 Pimavanserin 47 LY# [003] 47 HuMax CD4 47 randomized controlled Phase 47 NTx 47 tyrosine kinase inhibitor 47 Debio 47 Erbitux cetuximab 47 Fibrillex TM 47 VEGFR2 inhibitor 47 Hedgehog Pathway Inhibitor 47 bevacizumab Avastin ® 47 BEXXAR 47 ThermoDox R 47 farletuzumab 47 UA# 46 Golimumab 46 Phase 1b trial 46 phase IIb study 46 Provenge sipuleucel T 46 refractory gout 46 vismodegib 46 BRIM2 46 tezampanel 46 ENMD # 46 Romidepsin 46 ONCONASE 46 recurrent glioblastoma 46 Laquinimod 46 GSK# [001] 46 Cetrorelix 46 TELCYTA 46 PCK# 46 OHR/AVR# 46 sunitinib malate 46 APOPTONE 46 Alocrest 46 Phase Ib clinical trials 46 velafermin belinostat 46 mRCC 46 antifolates 46 Herceptin trastuzumab 46 Zybrestat 46 Tarceva TM 46 Neuradiab 46 Ocrelizumab 46 cabozantinib 46 DAVANAT 46 kinase inhibitor 46 mitogen activated ERK kinase 46 ixabepilone 46 leukemia AML 46 Phase IIb trials 46 IIa trial 46 Phase IIa clinical 46 Catena ® 46 phase IIa clinical 46 PSN# [002] 46 VELCADE melphalan 46 PANVAC VF 46 MAP# 46 PEP# [003] 46 omacetaxine mepesuccinate 46 OncoVEX GM CSF 46 lintuzumab 46 TLR8 agonist 46 assessing T DM1 46 bortezomib Velcade ® 46 NU# [001] 46 milatuzumab 46 zanolimumab 46 Zentaris GmbH 46 Cloretazine R 46 VAPRISOL 46 AMD# [003] 46 PDX pralatrexate 46 immunomodulator 46 AEZS 46 rindopepimut 46 talabostat 46 lintuzumab SGN 46 EFOY Pro 46 MB# [004] 46 lomitapide 46 valopicitabine 46 ANTEGREN 46 Synavive 46 TACI Ig 46 Avastin bevacizumab 46 Rituximab 46 AZD# 46 perifosine 46 mTOR inhibitor 46 Celgosivir 46 LHRH antagonist 46 neratinib 46 danoprevir 46 Sorafenib 46 leading oral taxane 46 Vandetanib 46 HE# [002] 46 Fludara 46 dextromethorphan quinidine 46 intravenous dosing 46 KRN# 46 tezampanel NGX# 46 Zenvia Phase III 46 palifosfamide 46 MGCD# [001] 46 Pivotal Phase III 46 SCH # 46 crizotinib PF # 46 pegylated liposomal doxorubicin 46 EOquin TM 46 VEGFR2 46 EGFR inhibitors 46 OncoVEX 46 preclinical studies 46 IPLEX 46 ITMN 45 resminostat 45 renin inhibitor 45 AP# [003] 45 Isis Pharma 45 Telaprevir 45 romidepsin 45 Phenoptin 45 axitinib 45 Vicinium TM 45 ON #.Na 45 Tanespimycin 45 Phase IIa trial 45 Radezolid 45 Triolex 45 celgosivir 45 dose cohort 45 darinaparsin 45 pharmacokinetic PK study 45 dose escalation clinical 45 Stedivaze 45 phase Ib 45 novel anticancer 45 Valortim 45 Vilazodone 45 MAXY G# 45 sodium thiosulfate STS 45 L Annamycin 45 GAP #B# 45 BZL# 45 brivaracetam 45 proprietary nanoparticle albumin 45 MabCampath 45 Cloretazine 45 NEUMUNE 45 RPTP 45 ALD# 45 Genz # 45 lorvotuzumab mertansine 45 ThermoDox ® 45 HspE7 45 Civacir 45 Asentar 45 registrational 45 Multiple Ascending Dose 45 Clavis Pharma ASA 45 GAMMAGARD 45 SNT MC# 45 miconazole Lauriad 45 Taxotere ® 45 GRN#L 45 Curaxin CBLC# 45 Virulizin R 45 MTR# 45 Leukine 45 Array BioPharma 45 JAK2 45 blinatumomab 45 FTY# 45 docetaxel chemotherapy 45 Hsp# inhibitors 45 elesclomol 45 MYDICAR ® 45 cell lymphoma CTCL 45 paclitaxel carboplatin 45 Imprime PGG 45 HCV 45 RDEA# 45 albinterferon alfa 2b 45 GSK # 45 Talabostat 45 TG# [003] 45 LEUKINE 45 Exherin TM 45 ProSavin 45 Pulse Width Modulation PWM 45 Phase 1a clinical 45 CA4P 45 bortezomib Velcade R 45 S/GSK# 45 Syncria 45 Darinaparsin 45 NP2 Enkephalin 45 AACR NCI EORTC 45 ELND# 45 RhuDex 45 Darusentan 45 Bendavia 45 SURFAXIN r 45 Luveniq 45 phase IIa 45 SCCHN 45 GlycoPEG GCSF 45 adecatumumab 45 eltrombopag 45 ARIKACE 45 favorable pharmacokinetic profile 44 samalizumab 44 GLPG# 44 teduglutide 44 ALN VSP 44 tamibarotene 44 preclinical 44 refractory AML 44 omacetaxine 44 bevacizumab Avastin 44 seliciclib 44 FavId 44 BRIM3 44 Vidofludimus 44 perifosine KRX 44 BrachySil 44 Tubulin 44 Phase 2b study 44 MOZOBIL 44 Alnylam ALNY 44 pharmacokinetic PK 44 XMT 44 rFIXFc 44 prulifloxacin 44 M8 M# 44 INGN 44 multicenter Phase II 44 glufosfamide 44 ALK inhibitor 44 entinostat 44 GVAX 44 Folotyn 44 plus gemcitabine 44 metastatic castration resistant 44 Motesanib 44 leverages albumin nanoparticles 44 Preclinical studies 44 abiraterone acetate 44 Phase IIb clinical 44 BIBW 44 relapsed refractory 44 regorafenib 44 Telcyta 44 SW# [003] 44 Zerenex 44 Urocortin 2 44 GvHD 44 IMGN# 44 ongoing Phase 1b 44 ruxolitinib 44 T#/T# 44 Phase II 44 Carfilzomib 44 metastatic RCC 44 nonclinical studies 44 imetelstat 44 Cethrin 44 Ceplene/IL-2 44 ofatumumab 44 phase IIb 44 ARQ 44 sapacitabine 44 heavily pretreated 44 Zolinza 44 ostarine 44 ISIS # 44 Pixantrone 44 Hsp# inhibitor 44 laquinimod 44 metastatic CRC 44 low dose cytarabine 44 CORT # 44 Phase III randomized controlled 44 TRV# [001] 44 Perifosine 44 anti leukemic 44 Satraplatin 44 investigational compound 44 refractory multiple myeloma 44 talactoferrin 44 sorafenib Nexavar 44 Exelixis XL# 44 atacicept 44 TRISENOX 44 G#A [001] 44 MEK inhibitor RDEA# 44 nab paclitaxel 44 randomized Phase 2b 44 BiDil XR 44 CTCE 44 IIIc 44 ara C 44 fostamatinib 44 Phase 2a clinical 44 CCR2 44 CTAP# Capsules 44 custirsen 44 PROMACTA 44 PRTX 44 Curis CRIS 43 GRN# 43 multiple ascending dose 43 Ipilimumab 43 Seliciclib 43 P2X 43 Ph3 43 Range Extender 43 Carotid WALLSTENT 43 tafamidis 43 gefitinib 43 tivozanib 43 TGF beta1 43 bafetinib 43 darapladib 43 OMAPRO 43 compound INCB# 43 C# C# [001] 43 Phase IIa 43 Allovectin 7 R 43 belinostat 43 Phase 2a 43 PF# [002] 43 apaziquone 43 Alpharadin 43 randomized discontinuation trial 43 betrixaban 43 pomalidomide 43 Desmoteplase 43 Sipuleucel T 43 alvimopan 43 IRX 2 43 refractory NSCLC 43 Marqibo 43 FOLFIRI 43 androgen independent 43 SUCCEED trial 43 Ceplene TM 43 nitazoxanide 43 Restanza 43 omecamtiv mecarbil 43 velafermin 43 vosaroxin 43 TYKERB 43 Nasulin 43 class mGluR5 inhibitor 43 telomerase inhibitor drug 43 plerixafor 43 muraglitazar 43 EFAPROXYN 43 REOLYSIN ® 43 XYOTAX 43 Kevetrin 43 INVISIO 43 Locteron 43 tesetaxel 43 Ophena TM 43 XL# SAR# 43 Phase III 43 AV2 43 IND enabling 43 ELACYT 43 PROSTVAC ® 43 Atiprimod 43 Junovan 43 IMP# 43 Vertex hepatitis C 43 T DM1 43 Ziopharm 43 ILLUMINATE 42 Miraxion 42 hematological cancers 42 OSI Pharma 42 sorafenib Nexavar ® 42 dose escalation Phase 42 pharmacokinetic profile 42 investigational oral 42 Vectibix 42 AEterna 42 tesmilifene 42 Corlux 42 LUX Lung 42 carboplatin paclitaxel 42 Reolysin 42 aflibercept 42 NASDAQ OMER 42 mGluR5 negative 42 Phase 1b clinical 42 Phase 2a trial 42 vandetanib 42 Huntexil 42 iSONEP 42 CLORETAZINE TM VNP#M 42 mCRC 42 rFVIIIFc 42 ADVEXIN 42 MLN# 42 Apolipoprotein 42 Revimmune 42 PRX # 42 Carotid 42 Phase 2b trial 42 Canvaxin 42 AZX# 42 tremelimumab 42 brentuximab vedotin 42 indolent NHL 42 vilazodone 42 Dr. Scangos 42 HT# [002] 42 ATZ 42 PREOS 42 Atu# 42 ProLindac 42 pro brain natriuretic 42 Chrysalin 42 Entereg R 42 PRECISE trial 42 MYDICAR 42 carfilzomib 42 decitabine 42 VentiRx 42 AZ# [001] 42 PARP1 42 DR Cysteamine 42 Xcyte 42 dosing cohort 42 DAVANAT R 42 ponatinib 42 mitomycin 42 ALTU 42 AVN# [001] 42 visilizumab 42 ® eculizumab 42 SUO 42 TGX 42 Phase IIb 42 aclidinium 42 LAB CGRP 42 FOLOTYN 42 ENMD 42 multicenter Phase 42 VN# [002] 42 PANC 42 Xacti VPC 42 bazedoxifene 42 ZYBRESTAT 42 QLT# 42 Viventia 42 Æterna Zentaris 41 NKTR 41 BR.# 41 CTA# Injection 41 Genasense ® 41 CRx 41 LymphoStat B 41 SinuNase 41 Leuprolide 41 ascending dose study 41 PEG Interferon lambda 41 Illumigen 41 TORISEL 41 Azixa 41 blinded randomized placebo controlled 41 INC# 41 CYT# 41 oncolytics 41 Serdaxin 41 LibiGel ® 41 Menerba 41 HER2 positive metastatic breast 41 cutaneous T cell 41 daclizumab 41 satraplatin Phase 41 #x#G [002] 41 ozarelix 41 transferase 41 xenograft models 41 vascular brachytherapy 41 tolerated dose MTD 41 viral kinetic 41 bicifadine 41 PS# [001] 41 Chemophase 41 RD# [002] 41 #ME# 41 voreloxin 41 dose escalation trial 41 brentuximab vedotin SGN 41 GetGoal Phase III 41 temsirolimus 41 Phenserine 41 Convivia 41 Cinryze ™ 41 Genasense 41 SPP# [001] 41 Hematide 41 Coherex 41 tosedostat 41 LBH# 41 conformal radiotherapy 41 Cotara 41 MetMAb 41 Presence Detection 41 IX# [002] 41 APPRAISE 41 Ostarine 41 fluticasone propionate FP 41 Alder Biopharmaceuticals 41 IDX# 41 SUTENT 41 small molecule chemotherapeutic 41 lupus nephritis 41 AstraZeneca Targacept 41 eculizumab 41 ATryn R 41 Nuvion 41 Annexin